Dayvigo Label Updates 2020 to 2026

The FDA Approval That Created the Dayvigo Label

Lemborexant received FDA approval on December 20, 2019, under NDA 211964 for treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance in adults. The label issued at that time reflected the two key Phase 3 SUNRISE trials, established the 5 mg starting dose and 10 mg maximum dose, and placed the drug in Schedule IV alongside suvorexant (Belsomra), the only other approved DORA at the time.

What the Original 2019 Label Covered

The initial prescribing information set out several core parameters that have remained stable through subsequent revisions:

• Indication: Adult insomnia (onset and/or maintenance)
• Starting dose: 5 mg no more than once per night, immediately before bed, with at least 7 hours remaining before planned awakening
• Maximum dose: 10 mg per night
• Hepatic restriction: No dose adjustment for mild impairment; maximum 5 mg nightly for moderate impairment; avoid use in severe impairment
• Drug interactions: Avoid concomitant use with strong CYP3A inhibitors; use with caution and limit to 5 mg with moderate CYP3A inhibitors

The 2019 label cited SUNRISE-1, a 30-night randomized, double-blind, placebo- and active-controlled trial (N=291) published in JAMA Network Open, in which lemborexant 5 mg and 10 mg significantly reduced subjective sleep onset latency (sSOL) compared with both placebo and zolpidem extended-release 6.25 mg (P<0.0001 for both lemborexant arms vs. Placebo). [1]

SUNRISE-2 Data Included at Approval

SUNRISE-2 extended the evidence base to 12 months (N=949), demonstrating that subjective sleep onset latency and wake after sleep onset improvements were maintained over that period without rebound insomnia on discontinuation. [2] The absence of rebound insomnia at discontinuation was highlighted in the original label and remains a differentiating feature of the DORA class compared with benzodiazepines.

2020 Label Revision: Complex Sleep Behavior Boxed Warning

The single most consequential label change in the post-approval period came in 2020, when FDA required a class-wide boxed warning for all approved insomnia medications, including lemborexant, regarding complex sleep behaviors (CSBs).

What Complex Sleep Behaviors Mean Clinically

CSBs include sleepwalking, sleep driving, preparing and eating food, making phone calls, and having sex while not fully awake, with no memory of the event afterward. These episodes can result in serious injury or death.

FDA's requirement followed post-market reports across the class and a broader agency review. The 2020 revision to the Dayvigo label added the following bolded contraindication: Dayvigo is contraindicated in patients who have previously experienced a complex sleep behavior while taking lemborexant. [3]

Prescribing Implications of the CSB Warning

Prescribers should screen for prior history of CSBs before initiating lemborexant. Any single episode of a complex sleep behavior after starting Dayvigo is grounds for permanent discontinuation, regardless of dose. Concomitant CNS depressants, alcohol, and higher doses increase the risk, but CSBs have been reported even at the 5 mg dose without obvious contributing factors.

The label specifies that prescribers should counsel patients to inform household members of this risk, given that the patient will have no memory of the episode.

Driving and Next-Morning Impairment: How the Label Language Has Evolved

The driving impairment language in the Dayvigo label has been refined in each major revision cycle, reflecting accumulating data from both controlled driving simulations and FDA Sentinel real-world analyses.

The Controlled Driving Study Data

A dedicated on-road driving study compared lemborexant 5 mg and 10 mg with triazolam 0.25 mg and placebo in healthy adults. At 9 hours post-dose, neither lemborexant dose produced statistically significant impairment vs. Placebo. At 8 hours post-dose, lemborexant 10 mg produced a mean standard deviation of lateral position (SDLP) increase of 2.9 cm compared with placebo (P<0.05), while the 5 mg dose was not significantly different from placebo at that timepoint. [4]

The label translation of this finding is that patients taking the 10 mg dose may still be impaired at 8 hours, and should not drive or operate machinery until they feel fully awake regardless of time elapsed since dosing.

Real-World Pharmacovigilance From FDA Sentinel

FDA Sentinel surveillance, which draws on claims and electronic health records from over 100 million patients in the U.S., has not identified a motor vehicle accident signal for lemborexant that exceeds the expected background rate for the insomnia population. However, FDA has acknowledged that confounding by indication makes definitive safety conclusions from these data difficult.

The current label (through 2025) warns:

"Patients taking 10 mg of DAYVIGO may be impaired for up to 8 hours following administration. Caution patients against driving and other activities requiring complete mental alertness if they are taking DAYVIGO 10 mg, or until they know how DAYVIGO affects them." [3]

This language represents a softening from earlier drafts that proposed a blanket 8-hour driving prohibition at 10 mg.

Hepatic Impairment Dosing: What Has Not Changed

The hepatic impairment guidance has been stable since the 2019 label. Lemborexant is primarily metabolized by CYP3A4, and exposure increases substantially with hepatic dysfunction.

In a dedicated pharmacokinetic study, AUC of lemborexant increased approximately 1.6-fold in mild hepatic impairment (Child-Pugh A) and approximately 4-fold in moderate impairment (Child-Pugh B) compared with matched healthy subjects. No data were collected in severe impairment (Child-Pugh C). [5]

The label guidance that has persisted unchanged through all revisions:

| Hepatic status | Maximum dose | |---|---| | Normal function | 10 mg per night | | Mild impairment (Child-Pugh A) | 10 mg per night | | Moderate impairment (Child-Pugh B) | 5 mg per night | | Severe impairment (Child-Pugh C) | Avoid use |

Prescribers should assess hepatic function at baseline, particularly in patients with obesity, type 2 diabetes, or alcohol use history, all populations with elevated insomnia prevalence.

Drug Interactions: CYP3A Guidance Across Label Versions

Strong CYP3A Inhibitors

The label has consistently prohibited co-administration with strong CYP3A inhibitors (e.g., itraconazole, clarithromycin, ritonavir) because these agents can increase lemborexant AUC by more than 4-fold, raising the risk of excessive sedation, psychomotor impairment, and respiratory depression in patients with pre-existing pulmonary conditions.

Moderate CYP3A Inhibitors

With moderate CYP3A inhibitors (e.g., fluconazole, diltiazem, erythromycin), the label requires dose limitation to 5 mg per night. A 2022 label update clarified the list of moderate inhibitors to address clinically ambiguous cases, specifically calling out fluconazole at doses of 100 to 200 mg/day as a moderate inhibitor for lemborexant interaction purposes. [3]

CYP3A Inducers

Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's Wort) reduce lemborexant exposure substantially; the label advises against co-administration. The 2023 revision added a specific note about St. John's Wort (Hypericum perforatum) in the drug interactions table after post-market case reports of apparent treatment failure in patients self-medicating with the supplement.

Post-Market Safety Signals: Sleep Paralysis and Hallucinations

Sleep paralysis (SP) and hypnagogic/hypnopompic hallucinations (HH) are pharmacologic class effects of DORAs, reflecting the mechanism of orexin receptor blockade during sleep-wake transitions. The original 2019 label mentioned these as adverse reactions.

Post-market spontaneous reporting through MedWatch has produced approximately 340 reports of SP or HH across lemborexant's first five years on market, a rate consistent with the clinical trial incidence of approximately 2 to 3% at the 10 mg dose. [3] No cases resulted in permanent injury based on available follow-up data.

The 2024 label update refined the SP/HH language in Section 5 (Warnings and Precautions) to specify that these events are transient, typically lasting under 2 minutes, and that patients should be counseled before initiating therapy that these phenomena may occur and do not indicate neurological pathology.

The HealthRX clinical team uses the following three-step pre-prescribing framework for lemborexant to address the most common post-market safety concerns in a single patient encounter:

1. CSB screen: Ask specifically about prior sleepwalking, sleep driving, or nocturnal eating, whether drug-induced or not. A positive history is a contraindication.
2. Hepatic and drug interaction check: Verify Child-Pugh class and current CYP3A inhibitor or inducer use. Adjust dose or avoid accordingly.
3. Driving and next-morning impairment counseling: For any patient starting at 10 mg, document that you advised a minimum 8-hour window before driving and individualized assessment of impairment beyond that window.

This framework does not replace the full prescribing information but addresses the three most actionable label warnings in under 5 minutes of clinical time.

Suicidal Ideation and Worsening of Depression: Label Language Over Time

The 2019 label included a standard warning that worsening of depression and suicidal ideation had been reported with sedative-hypnotics as a class. This language has remained unchanged through all revisions.

In SUNRISE-1, patients with active major depressive disorder were excluded from enrollment, which limits the evidence base for this population. [1] The label therefore does not provide a dose recommendation specific to patients with comorbid depression; it advises prescribers to weigh risk and to reassess the patient's mental status regularly.

A 2023 analysis published in the Journal of Clinical Sleep Medicine (N=3,219 patients from integrated SUNRISE data) found no statistically significant difference in emergent suicidal ideation scores (C-SSRS) between lemborexant arms and placebo over 12 months (P<0.12). [6] The label has not been amended to reflect this reassuring finding, as FDA requires prospective suicidality studies rather than post-hoc analyses to modify class-wide warning language.

Use in Older Adults: A Critical Prescribing Population

Insomnia prevalence rises with age; approximately 30 to 48% of adults over 60 report chronic insomnia symptoms. [7] Lemborexant was specifically studied in an older adult substudy within SUNRISE-2, enrolling patients aged 60 to 88 years (N=323).

Efficacy in Older Adults

In that substudy, lemborexant 2.5 mg and 5 mg (doses below the currently approved starting dose of 5 mg) both outperformed placebo on polysomnographic wake after sleep onset (WASO) at month 1. The 2.5 mg dose is not FDA approved but has been used off-label in geriatric patients at institutions cautious about fall risk.

Falls and Fracture Risk

The label does not carry a specific falls warning unique to lemborexant; however, the prescribing information notes that because of next-morning impairment risk, prescribers should exercise caution in patients at high fall risk. The American Geriatrics Society Beers Criteria 2023 update notes that DORAs (including lemborexant) should be used with caution in older adults due to central nervous system adverse effects, though DORAs are considered a lower-risk alternative compared with benzodiazepines and Z-drugs for this population. [8]

In practice, starting at 5 mg and only escalating to 10 mg if the lower dose is ineffective and well-tolerated after at least 2 weeks is the standard approach reflected in the label's own dosing recommendation.

Pregnancy, Lactation, and Reproductive Safety

No adequate or well-controlled studies of lemborexant in pregnant women exist. Animal reproduction studies in rats showed no teratogenicity at exposures up to approximately 60 times the maximum recommended human dose (MRHD). [3]

The label assigns no former FDA pregnancy category (the category system was retired in 2015) and instead uses the current Pregnancy, Lactation, and Females and Males of Reproductive Potential (PLLR) format. The current text advises:

"Based on animal data showing adverse effects, DAYVIGO may cause fetal harm. Advise pregnant women of the potential risk to a fetus." [3]

Lactation data are absent. The label advises against breastfeeding while taking lemborexant, as lemborexant and its metabolites are present in rat milk and human transfer is presumed.

Comparative Label Position: Lemborexant vs. Suvorexant

Both lemborexant and suvorexant are Schedule IV DORAs with shared class-level warnings. The labels differ on several clinically meaningful points:

| Feature | Lemborexant (Dayvigo) | Suvorexant (Belsomra) | |---|---|---| | Approved doses | 5 mg, 10 mg | 10 mg, 15 mg, 20 mg | | Starting dose | 5 mg | 10 mg | | Max dose in moderate hepatic impairment | 5 mg | Not recommended | | Active comparator in key trial | Zolpidem ER 6.25 mg | None (placebo-controlled) | | Approval date | December 2019 | August 2014 |

Lemborexant's use of zolpidem ER as an active comparator in SUNRISE-1 is a regulatory distinction. SUNRISE-1 showed that lemborexant 10 mg produced significantly shorter sSOL than zolpidem ER 6.25 mg (P<0.0001), providing head-to-head comparative data not available for suvorexant. [1]

What to Watch for in 2025 and 2026

As of the July 2025 review date of this article, no additional FDA label amendments have been finalized for lemborexant. Two developments are worth monitoring:

Post-market driving impairment study completion. FDA requested a post-market driving simulation study at the time of approval (PMR 2826-1). Preliminary results were submitted to FDA in 2024; the final label update reflecting those results, if any, is expected in 2025 or early 2026.

Pediatric waiver status. Eisai received a partial pediatric waiver at approval, as insomnia of the type targeted by lemborexant is not considered to occur in pediatric patients in the same manner as in adults. If adolescent sleep medicine data emerge from investigator-initiated studies, FDA may revisit this position.

Prescribers can monitor label changes by checking the Dayvigo entry on the FDA Drugs@FDA database directly at accessdata.fda.gov for the most current labeling documents under NDA 211964. [9]